Zevra Therapeutics, Inc. is rated a Buy, delivered robust FY25 results, with 350% revenue growth to $106.5M. Learn more about ZVRA stock here.

The FDA proposes new rules allowing mutation-specific gene therapies to qualify for approval despite extremely small patient ...